Biotech Co.* | Pharma Co. | Product | Terms/Details (Date) |
| |
|||
Aastrom | CDK Tibbi | Cell Production Products | Agreements expand the sales and marketing of Aastrom's Cell Production Products line in Italy and Turkey; CDK will distribute the line in Turkey, while Capitalife will assist Aastrom's subsidiary, Zellera AG, with marketing in Italy (1/13) |
Access Pharmaceuticals Inc. (AMEX:AKC) | Zambon Group | Amlexanox | Zambon gained exclusive marketing rights in France, Germany, Holland, Belgium, Luxembourg, Switzerland, Brazil and Columbia and a semi-exclusive license for Italy for amlexanox to treat canker sores; Zambon will pay an up-front licensing fee, make milestone payments and purchase the finished product from Access; the deal could generate up to $6.7M for Access (1/14) |
AEterna | German Remedies Ltd. (unit of the Zydus Cadila Group; India) | Impavido (miltefosine) | Agreement for German Remedies to market Impavido in India and Bangladesh (2/27) |
AEterna | Hainan Tianwang International Pharmaceutical Co. (China) | Lobaplatin | Hainan Tianwang will manufacture and market Lobaplatin in China; Zentaris will receive a one-time payment of C$4.5M (US$2.9M); Tianwang will manufacture and deliver Lobaplatin to Zentaris or its partners for marketing in all other countries (1/8) |
Altus Biologics | Dr. Falk Pharma GmbH (Germany) | TheraCLEC | Dr. Falk Pharma receives exclusive rights to market the product in Europe, while Altus maintains marketing rights throughout the rest of the world, as well as global manufacturing rights; Dr. Falk Pharma will make up-front and milestone payments to Altus, as well as royalty payments upon commercialization (2/12) |
Cangene Corp. | Baxter Healthcare | WinRho SDF | European marketing and distribution agreement for WinRho SDF; Baxter will market and distribute the product in Europe, excluding Portugal, for treating immune thrombocytopenic purpura (3/14) |
Cellegy Pharmaceuticals | PDI Inc. | Tostrex Gel | Exclusive license agreement to commercialize the product in North America; Cellegy received $15M, and will receive a $10M milestone payment contingent on FDA approval of Tostrex Gel; PDI also will make royalty payments on net sales, ranging from 20% to 30%; Cellegy will supply the product, but will be reimbursed for manufacturing costs (1/2) |
Crucell NV | Aventis Pasteur | Technology related to viral vaccines | Aventis Pasteur will use Crucell's cell-based vaccine manufacturing technology to develop and commercialize next-generation vaccines; Crucell will receive up-front payments, milestone payments and royalties on future product sales (1/27) |
DynPort Vaccine | MicroTest Laboratories Inc. | Recombinant vaccines against botulinum neurotoxins | MicroTest received a $1.22M contract to provide aseptic manufacturing support for the production of a series of recombinant vaccines (2/11) |
Eurand | Kyowa Hakko | An orally administered fast-melt tablet technology | Eurand acquired worldwide pharmaceutical rights to the technology, as well as the manufacturing processes for the product; it intends to market the product in combi- nation with Microcaps, its taste-masking technology (1/21) |
GeneLink Inc. | FoodScience | GeneLink's genetic assessment technology | The agreement authorizes FoodScience to distribute GeneLink's DNA Collection Kit and Nutragenetic Profile Assessments and related products (1/29) |
ILEX Oncology | Schering AG | Campath | Agreement giving Schering rights to develop, sell and distribute Campath in Japan, China and the Asian Pacific Basin (2/5) |
Ligand Pharmaceuticals | Organon Pharmaceuticals USA Inc. | Avinza | Co-promotion agreement for Avinza; it is set for 10 years and involves only the U.S.; Organon has an option to extend the agreement to 2017 by making a $75M payment to Ligand (2/25) |
SkyePharma | Shire Pharmaceuticals plc (UK) | Solaraze | Licensing agreement giving Shire exclusive rights to manufacture, distribute and sell Solaraze, a topical therapy for actinic keratosis, in Australia, New Zealand, South Africa and certain other countries in the Pacific Rim; Shire will receive up to 2.2M (US$3.5M) comprising an up-front payment and milestone payments (1/15) |
Trimeris Inc. | Chronimed Inc. | Fuzeon | U.S. distribution agreement for Fuzeon (3/20) |
| |
|||
Notes: |
|||
# The information in the chart does not cover agricultural agreements or those between biotech companies. |
|||
* Private companies are indicated with an asterisk. |
|||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. |
|||
AMEX = American Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange |
|||
To read more on related topics, click on one of the words below.